The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, but its position within the broader sector now raises questions about future returns . Generic versions are undercutting patent protection , prompting anxieties that investing in companies heavily reliant to Viagra's previous position could be a speculative strat